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During the last decades, emerging evidence has shown that
atherosclerosis is characterised by a complex endocrine,
paracrine and juxtacrine cross-talk between immune and
vascular cells as well as several tissues and organs,
including the liver, heart, kidney, adipose tissue, adrenal,
pancreatic, pituitary and sex glands [1]. Thus, atheroscle-
rosis has to be considered as a “systemic disease”,
characterised by arterial inflammatory lesions that mature
and modify themselves with disease progression. Athero-
sclerotic plaques are the battlefield among an unbalanced
immune response and lipid accumulation in the intima of
arteries. Although the “first event” favouring early lipid
deposition within the arterial sub-intimal space has not been
identified, the infiltration of low-density lipoproteins (LDL)
should be considered as the pivotal step in plaque formation
[2]. Oxidative and enzymatic modifications of retained
LDL increase the expression of adhesion molecules on
endothelial cell surface membrane, thus favouring leuko-
cyte recruitment from the blood stream [3]. Leukocytes
recruitment within atherosclerotic plaques is also orches-
trated by the chemokine binding to their receptors on cell
membrane. This is a redundant system which regulates all
inflammatory phases of atherogenesis in both humans and
animals [4]. Monocytes have been defined by Weber et al.
as the “crucial force” to drive atherogenesis [3]. In vivo
monocyte inflammatory functions and differentiation are
influenced by the different expression of chemokine
receptors, CD14 and CD16. Two different monocyte
subsets have been identified. Inflammatory monocyte
subset (CXC3CR1
lowCCR2+Ly6ChiCD14+CD16−) repre-
sents the main population recruited within the plaque from
the blood stream and display both phagocytic and proteo-
lytic activities. On the other hand, resident monocyte subset
(CXC3CR1
hiCCR2−Ly6ClowCD14lowCD16+) is the main
population involved in the initiation of tissue inflammation,
angiogenesis and atheroprogression [3]. Modified LDL are
uptaked by scavenger receptors of resident macrophages
that differentiate into different inflammatory cell types,
such as dendritic cells, foam cells, osteoclast- and
osteoblast-like cells. These processes are modulated by
several cytokines and growth factors (such as receptor
activator of nuclear factor [NF]kappaB ligand [RANKL],
osteoprotegerin [OPG], tumour necrosis factor [TNF]-
alpha, granulocyte macrophage-colony stimulating factor
[GM-CSF], macrophage-colony-stimulating factor [M-
CSF] and interleukin [IL]-4). On the other hand, connexins,
which mediate gap junction formation between adjacent
cells (vascular and immune cells), have been recently
shown to playing a crucial role in cell differentiation and
growth. Three different connexins (Cx37, Cx40 and Cx43)
are differently expressed in macrophage and endothelial
cells during atherosclerotic plaque maturation [5]. At this
step, the non-specific immune response, mainly character-
ised by local monocyte/macrophage-mediated inflammato-
ry processes has started. In a second phase, resident
inflammatory and vascular cells further produce chemo-
kines for the recruitment of T lymphocytes within the
plaque. This induces the deleterious vicious circle of the
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immune-mediated inflammatory response [6] TH1 lympho-
cytes, B cells, mast cells, neutrophils promote atheroscle-
rotic processes. Conversely, TH2 and Treg lymphocytes
rather reduce atherogenesis [3]. Both paracrine (chemo-
kines and cytokines) and juxtacrine (mediated by adhesion
molecules and connexins) communication pathways regu-
late leukocyte recruitment and intra-plaque activation [3, 5].
An altered balance between TH1 cytokines (interferon
[IFN]-gamma, IL-12, IL-15, IL-18 and TNF-alpha), anti-
inflammatory cytokines (TGF-beta and IL-10) and chemo-
kines (mainly CCL2, CCL3, CCL5) increase immune cell
functions and recruitment in atherosclerotic plaques. Adhe-
sion molecules on both leukocytes (integrins CD11a,
CD11b, CD11c, CD18 and selectins) and endothelial cells
(ICAMs, VCAMs, PECAMs and JAMs) mediate cell
rolling and adhesion to the vessel wall [7]. Local
inflammation triggers “systemic” organs to release soluble
inflammatory mediators, such as C-reactive protein (CRP),
endocannabinoids, cytokines (IL-6, TNF-alpha, IFN-
gamma and adipocytokines) and hormones that further
increase inflammation [8, 9]. All these factors have been
shown to directly induce both immune and vascular cell
activation. Smooth muscle cells migrate into the intima and
the arterial remodelling becomes irreversible which may
cause arterial lumen stenosis with collagen and calcium
deposition [9]. Once recruited into the intima, vascular and
immune cells also release toxic mediators, such as proteases
and oxidants that induce atherosclerotic plaque instability
until its possible rupture. This dramatic event causes the
exposure into the blood flow of intra-plaque pro-thrombotic
material with the consequent formation of a thrombus. The
sudden thrombotic occlusion of the artery at site of plaque
disruption can stop the blood flow and induce critical
ischemia in the heart, brain and peripheral tissues. The
present issue of the Seminars in Immunopathology will
focus on two different diseases, such as diabetes and sleep
apnea syndrome (SAS) [10, 11], strongly associated to
increased atherosclerosis and its dramatic complications.
Finally, the present issue we will also focus on some
promising therapies to reduce atherosclerosis. We will
update new insights in vaccination approach and cannabi-
noid or statin treatments. Cannabinoid treatment in basic
research, animal models and clinical studies reduced
atherosclerosis and the risk of the acute ischemic compli-
cations [12–15]. The use of selective peripheral blockade
of CB1 and/or the activation of CB2 cannabinoid receptors
might represent a most promising therapy. However, the
increase of major psychiatric adverse events that has been
recently reported in clinical trials investigating the role of
CB1 cannabinoid antagonist rimonabant in weight loss in
obese patients, has strongly limited this approach [15, 16].
Pleiotropic activities of statins represent another pivotal
pathway to reduce atherosclerosis. In November 2008,
Ridker et al. have shown that rosuvastatin significantly
reduced incidence of major cardiovascular events in a
population of healthy subjects with elevated high-
sensitivity levels of CRP and without hyperlipidemia
[17]. The efficacy of rosuvastatin in primary prevention
independently of cholesterol lowering strongly suggest
and support the use of these drugs to reduce CRP-
mediated pro-atherosclerotic risk. Together with vaccina-
tion approach, both cannabinoid and statin treatment will
represent some very important approaches to reduce
cardiovascular risk.
To summarise and introduce this issue, recent evidence
confirmed that immune and inflammatory processes play a
crucial role in all phases of atherosclerosis. Treatment with
anti-inflammatory drugs represents a promising therapeutic
approach to reduce atherosclerosis and its complications,
such as myocardial infarction and stroke. In the next years,
cardiovascular research will probably confirm that the
selective regulation of immune response and inflammation
will be the most important strategies to fight cardiovascular
diseases.
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